Tongue Nerve Stimulator Does Good for Sleep Apnea Patients
Targeted hypoglossal nerve stimulation (THN) showed safety and efficacy for patients with moderate-to-severe obstructive sleep apnea (OSA), the randomized THN3 trial found. Four months after receiving a THN device, patients who had had their devices activated at month 1 were more likely to meet criteria for treatment response in terms of reduced apnea-hypopnea index (AHI; […]
First TYK2 Inhibitor for Psoriasis Wins FDA Approval
The FDA approved the first-in-class oral tyrosine kinase 2 (TYK2) inhibitor deucravacitinib (Sotyktu) for moderate-to-severe plaque psoriasis, Bristol Myers Squibb announced. The indication limits use to adults who are candidates for systemic therapy or phototherapy. Deucravacitinib is not recommended for use with other immunosuppressant drugs. “Sotyktu has the potential to become the new standard-of-care oral […]
International study supports dupilumab for treatment of moderate-to-severe asthma in children
A new medication has been added to the treatment options for children with moderate-to-severe asthma. In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11. The findings of the international multicenter Liberty Asthma VOYAGE trial, reported […]